T. W. Kim

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

Matthew D. Hellmann, T. W. Kim, Chul‐min Lee et al. · Annals of Oncology · 2019 · 190 citations · Full text

Medicine, Oncology, Pharmacology +11

Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells

Eui Man Jeong, Han-Sol Bae, T. W. Kim et al. · Oncogene · 2009 · 126 citations

Life Sciences, Cell Biology, Oncology +17

Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma

Zheng‐Hui Guan, Yan Wang, S Maoleekoonpairoj et al. · British Journal of Cancer · 2003 · 56 citations · Full text

Medicine, Oncology, Pharmacology +15

Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis

Jae‐Cheol Jo, J.-L. Lee, M.-H. Ryu et al. · Japanese Journal of Clinical Oncology · 2007 · 43 citations

Medicine, Oncology, Pharmacology +12

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

K-p Kim, Geundoo Jang, Yuancheng Hong et al. · British Journal of Cancer · 2011 · 32 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15